47.51
price up icon0.12%   0.02
 
loading
전일 마감가:
$47.49
열려 있는:
$47.46
하루 거래량:
967.33K
Relative Volume:
0.34
시가총액:
$114.77B
수익:
$49.41B
순이익/손실:
$5.59B
주가수익비율:
18.42
EPS:
2.5789
순현금흐름:
$12.54B
1주 성능:
+1.08%
1개월 성능:
-1.29%
6개월 성능:
+2.96%
1년 성능:
-10.07%
1일 변동 폭
Value
$47.35
$47.62
1주일 범위
Value
$47.20
$48.60
52주 변동 폭
Value
$44.62
$60.12

사노피 ADR Stock (SNY) Company Profile

Name
명칭
Sanofi Adr
Name
전화
-
Name
주소
-
Name
직원
82,878
Name
트위터
@sanofi
Name
다음 수익 날짜
2026-01-29
Name
최신 SEC 제출 서류
Name
SNY's Discussions on Twitter

Compare SNY vs LLY, JNJ, ABBV, MRK, NVS

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
SNY
Sanofi Adr
47.52 114.70B 49.41B 5.59B 12.54B 2.5789
Drug Manufacturers - General icon
LLY
Lilly Eli Co
1,054.96 913.67B 65.18B 20.64B 6.44B 22.96
Drug Manufacturers - General icon
JNJ
Johnson Johnson
239.35 572.91B 94.19B 26.80B 20.46B 11.05
Drug Manufacturers - General icon
ABBV
Abbvie Inc
223.62 387.09B 61.16B 4.20B 19.68B 2.3671
Drug Manufacturers - General icon
MRK
Merck Co Inc
122.53 297.22B 65.00B 18.26B 13.05B 7.2751
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
155.15 293.76B 54.72B 14.02B 15.32B 7.1855

사노피 ADR Stock (SNY) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2026-01-27 개시 Citigroup Neutral
2026-01-16 다운그레이드 UBS Buy → Neutral
2026-01-06 다운그레이드 Barclays Overweight → Equal Weight
2025-12-09 다운그레이드 Guggenheim Buy → Neutral
2025-12-08 다운그레이드 JP Morgan Overweight → Neutral
2025-09-08 업그레이드 Morgan Stanley Equal-Weight → Overweight
2025-09-02 업그레이드 Deutsche Bank Hold → Buy
2025-08-08 업그레이드 JP Morgan Neutral → Overweight
2025-04-15 개시 Exane BNP Paribas Outperform
2025-03-21 개시 Goldman Neutral
2025-01-30 업그레이드 Deutsche Bank Sell → Hold
2024-07-26 재확인 Argus Buy
2024-01-23 개시 Morgan Stanley Equal-Weight
2024-01-16 재개 UBS Buy
2023-12-05 다운그레이드 JP Morgan Overweight → Neutral
2023-10-30 다운그레이드 Stifel Buy → Hold
2023-09-06 업그레이드 Berenberg Hold → Buy
2023-07-14 개시 HSBC Securities Buy
2023-04-28 다운그레이드 Deutsche Bank Hold → Sell
2023-03-27 업그레이드 Barclays Equal Weight → Overweight
2022-12-13 재개 Morgan Stanley Overweight
2022-08-12 업그레이드 Deutsche Bank Sell → Hold
2022-08-09 다운그레이드 UBS Buy → Neutral
2022-05-23 개시 SVB Leerink Outperform
2021-09-27 업그레이드 SVB Leerink Mkt Perform → Outperform
2021-01-15 개시 Deutsche Bank Sell
2020-09-29 개시 Berenberg Hold
2020-03-17 업그레이드 Barclays Underweight → Equal Weight
2020-03-11 업그레이드 Goldman Neutral → Buy
2020-02-11 개시 SVB Leerink Mkt Perform
2020-01-06 업그레이드 JP Morgan Neutral → Overweight
2019-09-23 업그레이드 Guggenheim Neutral → Buy
2019-09-20 업그레이드 Morgan Stanley Equal-Weight → Overweight
2019-09-03 개시 Bernstein Outperform
2019-08-14 업그레이드 UBS Neutral → Buy
2018-12-11 업그레이드 Jefferies Hold → Buy
2018-11-01 업그레이드 Barclays Underweight → Equal Weight
2018-10-09 개시 Guggenheim Neutral
2018-09-10 업그레이드 BofA/Merrill Neutral → Buy
2018-08-10 업그레이드 Citigroup Neutral → Buy
2018-03-23 업그레이드 Liberum Hold → Buy
2018-01-23 다운그레이드 Barclays Equal Weight → Underweight
2017-12-06 다운그레이드 BofA/Merrill Buy → Neutral
2017-12-01 다운그레이드 Morgan Stanley Overweight → Underweight
2017-11-15 업그레이드 Barclays Underweight → Equal Weight
2017-08-30 업그레이드 HSBC Securities Reduce → Hold
모두보기

사노피 ADR 주식(SNY)의 최신 뉴스

pulisher
05:00 AM

Anti-Obesity Drugs Market to Reach US$195.99 Billion by 2036 as GLP-1 Therapies Drive a Structural Shift in Weight Management - GlobeNewswire Inc.

05:00 AM
pulisher
Feb 03, 2026

Is Sanofi SA (SNY) One of the Best Cheap Stocks to Buy for 2026 - Finviz

Feb 03, 2026
pulisher
Feb 02, 2026

Sanofi Found In Breach Of UK Pharmaceutical Marketing Code Over Beyfortus Claims - Sahm

Feb 02, 2026
pulisher
Feb 02, 2026

FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Feb 02, 2026
pulisher
Feb 02, 2026

Sanofi Plans Regulatory Submission For Investigational Drug For Rare Disease Despite Mixed Data From Pivotal Trials - Sahm

Feb 02, 2026
pulisher
Jan 30, 2026

REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth - Finviz

Jan 30, 2026
pulisher
Jan 30, 2026

European ADRs Slip, But Still End The Week Higher - Finimize

Jan 30, 2026
pulisher
Jan 30, 2026

Sanofi ADR earnings beat by $0.69, revenue fell short of estimates - Investing.com South Africa

Jan 30, 2026
pulisher
Jan 29, 2026

SNY Stock Today: January 30 RSV Wave in Germany Puts Beyfortus in Focus - Meyka

Jan 29, 2026
pulisher
Jan 29, 2026

TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz

Jan 29, 2026
pulisher
Jan 29, 2026

Earnings call transcript: Sanofi Q4 2025 earnings beat EPS forecast - Investing.com

Jan 29, 2026
pulisher
Jan 26, 2026

Berenberg Bank Remains a Buy on Sanofi (SNY) - Finviz

Jan 26, 2026
pulisher
Jan 26, 2026

Corticosteroids Market Report 2026 - GlobeNewswire Inc.

Jan 26, 2026
pulisher
Jan 21, 2026

Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer - Finviz

Jan 21, 2026
pulisher
Jan 18, 2026

The Truth About Sanofi S.A.: Is This Pharma Giant the Sleeper Stock Everyone’s Sleeping On? - AD HOC NEWS

Jan 18, 2026
pulisher
Jan 16, 2026

Sanofi (SNY) Secures Approval for Cablivi in the US and Plozasiran in China - Finviz

Jan 16, 2026
pulisher
Jan 16, 2026

FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz

Jan 16, 2026
pulisher
Jan 15, 2026

Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week? - Finviz

Jan 15, 2026
pulisher
Jan 13, 2026

Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz

Jan 13, 2026
pulisher
Jan 12, 2026

Sanofi (SNY) Reports Regulatory Win, Barclays Downgrades to 'Equal Weight' with EUR 85 PT - Finviz

Jan 12, 2026
pulisher
Jan 10, 2026

The Truth About Sanofi S.A.: Is This ‘Boring’ Pharma Stock a Secret Power Play? - AD HOC NEWS

Jan 10, 2026
pulisher
Jan 09, 2026

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail

Jan 09, 2026
pulisher
Jan 07, 2026

Regeneron Just Moved From Underperform To Buy - Benzinga

Jan 07, 2026
pulisher
Jan 05, 2026

KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? - Finviz

Jan 05, 2026
pulisher
Jan 05, 2026

Flu Season's Here-This Dividend-Payer Controls the Shot Market - Finviz

Jan 05, 2026
pulisher
Jan 05, 2026

FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children - Finviz

Jan 05, 2026
pulisher
Jan 02, 2026

REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? - Finviz

Jan 02, 2026
pulisher
Dec 31, 2025

Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026 - Sahm

Dec 31, 2025
pulisher
Dec 30, 2025

Jefferies Maintains Buy on Sanofi (SNY) Despite Regulatory Overhang - Finviz

Dec 30, 2025
pulisher
Dec 30, 2025

Where is Sanofi (SNY) Headed According to Wall Street? - Finviz

Dec 30, 2025
pulisher
Dec 29, 2025

Delayed MS Decision and Trial Miss Add to Sanofi's R&D Challenges - Finviz

Dec 29, 2025
pulisher
Dec 28, 2025

Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX) - Finviz

Dec 28, 2025
pulisher
Dec 25, 2025

Total debt per share of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView — Track All Markets

Dec 25, 2025
pulisher
Dec 24, 2025

Why Dynavax Stock Soared Today - Finviz

Dec 24, 2025
pulisher
Dec 24, 2025

Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise - Finviz

Dec 24, 2025
pulisher
Dec 24, 2025

Sanofi Makes $2.2 Billion Bet On Adult Vaccines With Dynavax Buy - Sahm

Dec 24, 2025
pulisher
Dec 24, 2025

Our Environmental Impact - Sanofi

Dec 24, 2025
pulisher
Dec 21, 2025

Bloom Energy Aktie: KI-Boom trifft auf Energiekrise! - Finanztrends

Dec 21, 2025
pulisher
Dec 17, 2025

Sanofi (SNY) Shares Under Pressure After JPMorgan and Guggenheim Downgrades - Finviz

Dec 17, 2025

사노피 ADR (SNY) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_general PFE
$27.11
price up icon 2.30%
$150.25
price up icon 0.60%
$374.91
price up icon 1.77%
drug_manufacturers_general NVO
$46.72
price up icon 7.81%
drug_manufacturers_general AZN
$190.92
price up icon 1.91%
drug_manufacturers_general NVS
$155.26
price up icon 0.81%
자본화:     |  볼륨(24시간):